QOL-21. Language development and outcomes in pediatric brain tumor. (3rd June 2022)
- Record Type:
- Journal Article
- Title:
- QOL-21. Language development and outcomes in pediatric brain tumor. (3rd June 2022)
- Main Title:
- QOL-21. Language development and outcomes in pediatric brain tumor
- Authors:
- Janke, Kelly
Paltin, Iris
Schofield, Hannah
Sy, Megan
Kearns, Zoe - Abstract:
- Abstract: RATIONALE: Pediatric brain tumor (PBT) survivors are at risk for speech (e.g., articulation, prosody, fluency) and language (e.g., vocabulary, grammar, narratives, pragmatics) difficulties, though group outcomes vary with study design and individual risk factors (Hodges et al 2020). This study characterizes language functioning for clinically referred PBT survivors diagnosed in early childhood, a time of rapid language development and vulnerability. METHODS : Participants were 98 PBT patients (56 supratentorial) diagnosed by age 6 (M = 43.8 months, SD 24.4) who received tumor-directed intervention (surgery, chemotherapy, and/or radiation). Age at neuropsychological evaluation (2019 – 2022) was 2-19 years (M = 9.1, SD 4.1). Patients were 56% male, 73.5% White, and fluent English speakers. Verbal IQ, naming, working memory, fluency, comprehension, syntactic and phonological processing, and parent-reported functional communication outcomes were assessed. Rates of weak performance (1 SD<Mean) were compared to the expected base rate of 16%. RESULTS : Group means significantly diverged from age-expected performance in all domains except fluency. IQ correlated with most language measures, age at diagnosis (r .280, p .010), and time from diagnosis (r -.276, p .012). Weakness was identified on at least 1 verbal subtests for 71.4% of the full sample and most (57%) patients with IQ>84. Patients with NF1 (n=15) or treatment-related hearing concerns had lower reportedAbstract: RATIONALE: Pediatric brain tumor (PBT) survivors are at risk for speech (e.g., articulation, prosody, fluency) and language (e.g., vocabulary, grammar, narratives, pragmatics) difficulties, though group outcomes vary with study design and individual risk factors (Hodges et al 2020). This study characterizes language functioning for clinically referred PBT survivors diagnosed in early childhood, a time of rapid language development and vulnerability. METHODS : Participants were 98 PBT patients (56 supratentorial) diagnosed by age 6 (M = 43.8 months, SD 24.4) who received tumor-directed intervention (surgery, chemotherapy, and/or radiation). Age at neuropsychological evaluation (2019 – 2022) was 2-19 years (M = 9.1, SD 4.1). Patients were 56% male, 73.5% White, and fluent English speakers. Verbal IQ, naming, working memory, fluency, comprehension, syntactic and phonological processing, and parent-reported functional communication outcomes were assessed. Rates of weak performance (1 SD<Mean) were compared to the expected base rate of 16%. RESULTS : Group means significantly diverged from age-expected performance in all domains except fluency. IQ correlated with most language measures, age at diagnosis (r .280, p .010), and time from diagnosis (r -.276, p .012). Weakness was identified on at least 1 verbal subtests for 71.4% of the full sample and most (57%) patients with IQ>84. Patients with NF1 (n=15) or treatment-related hearing concerns had lower reported functional communication. Naming difficulty was associated with supratentorial tumors; there were no other significant differences by tumor type or location. While functional communication correlated with several measures, weaknesses on performance-based and parent-report measures only corresponded for 44.6% of the sample. CONCLUSIONS : Language weaknesses are prevalent following early childhood PBT diagnosis. IQ and functional communication measures are useful indicators of risk, but more detailed and higher-level language measures are needed, particularly for cognitively intact patients. Additional implications and research needs will be discussed. … (more)
- Is Part Of:
- Neuro-oncology. Volume 24(2022)Supplement 1
- Journal:
- Neuro-oncology
- Issue:
- Volume 24(2022)Supplement 1
- Issue Display:
- Volume 24, Issue 1 (2022)
- Year:
- 2022
- Volume:
- 24
- Issue:
- 1
- Issue Sort Value:
- 2022-0024-0001-0000
- Page Start:
- i138
- Page End:
- i138
- Publication Date:
- 2022-06-03
- Subjects:
- Brain Neoplasms -- Periodicals
Brain -- Tumors -- Periodicals
Brain -- Cancer -- Periodicals
Nervous system -- Cancer -- Periodicals
616.99481 - Journal URLs:
- http://neuro-oncology.dukejournals.org/ ↗
http://neuro-oncology.oxfordjournals.org/ ↗
http://www.oxfordjournals.org/content?genre=journal&issn=1522-8517 ↗
http://ukcatalogue.oup.com/ ↗ - DOI:
- 10.1093/neuonc/noac079.504 ↗
- Languages:
- English
- ISSNs:
- 1522-8517
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6081.288000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 21906.xml